These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 21351562)

  • 1. [Progress in the study of tubulin inhibitors].
    Shang H; Pan L; Yang S; Chen H; Cheng MS
    Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 1-phenyl-1,2,3,4-dihydroisoquinoline compounds as tubulin polymerization inhibitors.
    Zheng CH; Chen J; Liu J; Zhou XT; Liu N; Shi D; Huang JJ; Lv JG; Zhu J; Zhou YJ
    Arch Pharm (Weinheim); 2012 Jun; 345(6):454-62. PubMed ID: 22415658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents.
    Patil SA; Patil R; Miller DD
    Future Med Chem; 2012 Oct; 4(16):2085-115. PubMed ID: 23157240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents.
    Chang JY; Yang MF; Chang CY; Chen CM; Kuo CC; Liou JP
    J Med Chem; 2006 Oct; 49(21):6412-5. PubMed ID: 17034147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tubulin inhibitors: a patent review.
    Liu YM; Chen HL; Lee HY; Liou JP
    Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.
    Coluccia A; Sabbadin D; Brancale A
    Eur J Med Chem; 2011 Aug; 46(8):3519-25. PubMed ID: 21621885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors.
    Ouyang X; Chen X; Piatnitski EL; Kiselyov AS; He HY; Mao Y; Pattaropong V; Yu Y; Kim KH; Kincaid J; Smith L; Wong WC; Lee SP; Milligan DL; Malikzay A; Fleming J; Gerlak J; Deevi D; Doody JF; Chiang HH; Patel SN; Wang Y; Rolser RL; Kussie P; Labelle M; Tuma MC
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5154-9. PubMed ID: 16198562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of silicon-containing tubulin polymerization inhibitors: replacement of the ethylene moiety of combretastatin A-4 with a silicon linker.
    Nakamura M; Kajita D; Matsumoto Y; Hashimoto Y
    Bioorg Med Chem; 2013 Dec; 21(23):7381-91. PubMed ID: 24139940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 2-step synthesis of Combretastatin A-4 and derivatives as potent tubulin assembly inhibitors.
    Barnes NG; Parker AW; Ahmed Mal Ullah AA; Ragazzon PA; Hadfield JA
    Bioorg Med Chem; 2020 Oct; 28(19):115684. PubMed ID: 32912434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of apoptosis through tubulin inhibition in human cancer cells by new chromene-based chalcones.
    Aryapour H; Riazi GH; Ahmadian S; Foroumadi A; Mahdavi M; Emami S
    Pharm Biol; 2012 Dec; 50(12):1551-60. PubMed ID: 22984888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs.
    Fürst R; Zupkó I; Berényi A; Ecker GF; Rinner U
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6948-51. PubMed ID: 19879758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents.
    Ruan BF; Lu X; Li TT; Tang JF; Wei Y; Wang XL; Zheng SL; Yao RS; Zhu HL
    Bioorg Med Chem; 2012 Jan; 20(2):1113-21. PubMed ID: 22189271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin-A4 as novel antitubulin agents.
    Hu Y; Lu X; Chen K; Yan R; Li QS; Zhu HL
    Bioorg Med Chem; 2012 Jan; 20(2):903-9. PubMed ID: 22192936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
    Bhattacharyya B; Panda D; Gupta S; Banerjee M
    Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
    Fürst R; Vollmar AM
    Pharmazie; 2013 Jul; 68(7):478-83. PubMed ID: 23923626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic activity and cytostatic mechanism of novel 2-arylbenzo[b]furans.
    Yang H; Pang JY; Cai YC; Xu ZL; Xian LJ
    J Pharm Pharmacol; 2006 Sep; 58(9):1281-7. PubMed ID: 16945188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
    Zhu C; Zuo Y; Wang R; Liang B; Yue X; Wen G; Shang N; Huang L; Chen Y; Du J; Bu X
    J Med Chem; 2014 Aug; 57(15):6364-82. PubMed ID: 25061803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors.
    Nien CY; Chen YC; Kuo CC; Hsieh HP; Chang CY; Wu JS; Wu SY; Liou JP; Chang JY
    J Med Chem; 2010 Mar; 53(5):2309-13. PubMed ID: 20148562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.